Patents by Inventor Aleem Gangjee

Aleem Gangjee has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof
    Patent number: 9556198
    Abstract: The present invention provides tricyclic compounds, pharmaceutically acceptable salts, solvates, or hydrates thereof, having antimitotic activity, anti-multidrug resistance activity, for example P-glycoprotein inhibition, and antitumor activity, and which inhibit paclitaxel sensitive and resistant tumor cells. Also provided are methods of utilizing these compounds for treating tumor cells and inhibiting mitosis of cancerous cells.
    Type: Grant
    Filed: April 29, 2015
    Date of Patent: January 31, 2017
    Assignee: Duquesne University of the Holy Spirit
    Inventor: Aleem Gangjee
  • Tricyclic Compounds Having Antimitotic and/or Antitumor Activity and Methods of Use Thereof
    Publication number: 20170022217
    Abstract: The present invention provides tricyclic compounds, pharmaceutically acceptable salts, prodrugs, solvates, or hydrates thereof, having antimitotic activity, anti-multidrug resistance activity, for example P-glycoprotein inhibition, and antitumor activity, and which inhibit paclitaxel sensitive and resistant tumor cells. Also provided are methods of utilizing these compounds for treating tumor cells and inhibiting mitosis of cancerous cells.
    Type: Application
    Filed: October 3, 2016
    Publication date: January 26, 2017
    Inventor: Aleem Gangjee
  • SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES FOR SELECTIVELY TARGETING TUMOR CELLS WITH FR-ALPHA AND FR-BETA TYPE RECEPTORS
    Publication number: 20170015672
    Abstract: Pyrrolo[2,3-d]pyrimidine derivatives, and pharmaceutical acceptable salts thereof, useful in therapeutically treating patients with cancer are disclosed. These compounds selectively target folate receptors (FR) of cancerous tumor cells and inhibit purine synthesis and hence, DNA synthesis.
    Type: Application
    Filed: September 29, 2016
    Publication date: January 19, 2017
    Applicants: DUQUESNE UNIVERSITY OF THE HOLY GHOST, WAYNE STATE UNIVERSITY
    Inventors: ALEEM GANGJEE, LARRY H. MATHERLY
  • Tricyclic Compounds Having Cytostatic and/or Cytotoxic Activity and Methods of Use Thereof
    Publication number: 20160355520
    Abstract: The present invention provides tricyclic compounds having cytostatic and cytotoxic activity in a single molecule having receptor tyrosine kinase(s), dihydrofolate reductase, thymidylate synthase and/or dihydroorotate dehydrogenase inhibitory activity, which are useful as anti-angiogenic and anti-tumor agents. Also provided are methods of utilizing these inhibitors to treat tumor cells and other proliferative diseases and disorders.
    Type: Application
    Filed: August 22, 2016
    Publication date: December 8, 2016
    Inventor: Aleem Gangjee
  • Selective proton coupled folate transporter and folate receptor, and GRAFTase inhibitor compounds and methods of using the same
    Patent number: 9511069
    Abstract: Fused cyclic pyrimidine compounds, including tautomers thereof, and pharmaceutically acceptable salts, prodrugs, solvates and hydrates thereof, are disclosed having the general Formula 1: These compounds are useful in methods for treating cancer, selectively targeting cancerous cells via the proton coupled folate transporter, folate receptor alpha, and/or folate receptor beta pathways, inhibiting GARFTase in cancerous cells, and selectively targeting activated macrophages in a patient having an autoimmune disease, such as rheumatoid arthritis.
    Type: Grant
    Filed: July 26, 2012
    Date of Patent: December 6, 2016
    Assignees: Duquesne University of the Holy Spirit, Wayne State University
    Inventors: Aleem Gangjee, Larry H. Matherly
  • Substituted pyrrolo[2,3-D]dipyrimidines for selectively targeting tumor cells with FR-alpha and FR-beta type receptors
    Patent number: 9481678
    Abstract: Pyrrolo[2,3-d]pyrimidine derivatives, and pharmaceutical acceptable salts thereof, useful in therapeutically treating patients with cancer are disclosed. These compounds selectively target folate receptors (FR) of cancerous tumor cells and inhibit purine synthesis and hence, DNA synthesis.
    Type: Grant
    Filed: February 9, 2015
    Date of Patent: November 1, 2016
    Assignees: Duquesne University of the Holy Ghost, Wayne State University
    Inventors: Aleem Gangjee, Larry H. Matherly
  • Cyclopenta[d]pyrimidines And Substituted Cyclopenta[d]pyrimidines As Antitubulin and Microtubule Targeting Agents, Monocyclic Pyrimidines As Tubulin Inhibitors, And Pyrrolopyrimidines As Targeted Antifolates And Tubulin and Multiple Receptor Tyrosine Kinase Inhibition And Antitumor Agents
    Publication number: 20160304525
    Abstract: The present invention provides a compound of Formula I, and salts thereof, and a pharmaceutical composition comprising a compound of Formula I: wherein R1 is selected from the group consisting of and R2 is an alkyl group having from one to ten carbon atoms, or wherein R2 is selected from the group consisting of R1 is an alkyl group having from one to ten carbon atoms; and R is H, or an alkyl group having from one to ten carbon atoms, and R3 is H, an alkyl group having from one to ten carbon atoms, or a halogen. Preferably the compound of Formula V includes wherein R3 is a halogen, and most preferably wherein the halogen is chlorine. Methods of treating a patient with cancer with these compounds are also provided.
    Type: Application
    Filed: April 15, 2016
    Publication date: October 20, 2016
    Inventor: Aleem Gangjee
  • Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof
    Patent number: 9458167
    Abstract: The present invention provides tricyclic compounds, pharmaceutically acceptable salts, prodrugs, solvates, or hydrates thereof, having antimitotic activity, anti-multidrug resistance activity, for example P-glycoprotein inhibition, and antitumor activity, and which inhibit paclitaxel sensitive and resistant tumor cells. Also provided are methods of utilizing these compounds for treating tumor cells and inhibiting mitosis of cancerous cells.
    Type: Grant
    Filed: May 22, 2015
    Date of Patent: October 4, 2016
    Assignee: Duquesne University of the Holy Spirit
    Inventor: Aleem Gangjee
  • Methods of using selective chemotherapeutic agents for targeting tumor cells
    Patent number: 9446045
    Abstract: A method for treating cancer tumors, particularly ovarian cancer tumors, is described, where fused cyclic pyrimidine having a cancer treating ability is selectively delivered to an FR expressing cancerous tumor.
    Type: Grant
    Filed: January 8, 2015
    Date of Patent: September 20, 2016
    Assignees: Duquesne University of the Holy Ghost, Wayne State University
    Inventors: Aleem Gangjee, Larry H. Matherly
  • Tricyclic compounds having cytostatic and/or cytotoxic activity and methods of use thereof
    Patent number: 9422297
    Abstract: The present invention provides tricyclic compounds having cytostatic and cytotoxic activity in a single molecule having receptor tyrosine kinase(s), dihydrofolate reductase, thymidylate synthase and/or dihydroorotate dehydrogenase inhibitory activity, which are useful as anti-angiogenic and anti-tumor agents. Also provided are methods of utilizing these inhibitors to treat tumor cells and other proliferative diseases and disorders.
    Type: Grant
    Filed: September 25, 2014
    Date of Patent: August 23, 2016
    Assignee: Duquesne University of the Holy Ghost
    Inventor: Aleem Gangjee
  • SUBSTITUTED PYRROLO[2,3-D]DIPYRIMIDINES FOR SELECTIVELY TARGETING TUMOR CELLS WITH FR-ALPHA AND FR-BETA TYPE RECEPTORS
    Publication number: 20160229857
    Abstract: Pyrrolo[2,3-d]pyrimidine derivatives, and pharmaceutical acceptable salts thereof, useful in therapeutically treating patients with cancer are disclosed. These compounds selectively target folate receptors (FR) of cancerous tumor cells and inhibit purine synthesis and hence, DNA synthesis.
    Type: Application
    Filed: February 9, 2015
    Publication date: August 11, 2016
    Applicant: Duquesne University of The Holy Ghost
    Inventors: ALEEM GANGJEE, LARRY H. MATHERLY
  • Conformationally Restricted 4-Substituted-2,6-dimethylfuro[2,3-d]pyrimidines as Multi-targeted Receptor Tyrosine Kinase Inhibitors and Microtubule Targeting Antitumor Agents
    Publication number: 20160176891
    Abstract: Compounds of Formula I: and compounds of Formula II: are provided. Pharmaceutical compositions comprising either the compound of Formula I or Formula II are disclosed. Methods of treating patients having cancer are provided by administering to the patient a therapeutically effective amount of one or more compounds having Formula I or Formula II to treat the patient. The compounds of Formula I or II are preferably conformationally restricted furo[2,3-d]pyrimidines having dual inhibition of microtubule assembly and receptor tyrosine kinases.
    Type: Application
    Filed: December 16, 2015
    Publication date: June 23, 2016
    Inventor: Aleem Gangjee
  • Substituted Pyrimidine Compounds and Methods of Use and Manufacture
    Publication number: 20160039830
    Abstract: This invention provides substituted pyrimidine compounds having the formula: wherein X is absent, CH2, S, or O, and R is an alkyl group having from one to ten carbon atoms, and optionally salts, hydrates, or solvates thereof, that are useful in treating a patient having a disease or cancer. The compounds of this invention are useful as multi-enzyme antifolates selectively targeting the folate receptor (FR). Further, a method of making 5- and 6-substituted cyclopenta[d]pyrimidine for nonclassical and classical antifolates as TS and DHFR inhibitors is provided.
    Type: Application
    Filed: August 7, 2015
    Publication date: February 11, 2016
    Inventors: Aleem Gangjee, Larry H. Matherly
  • Pyrimidine Compounds and Pyrimido Indole Compounds and Methods of Use
    Publication number: 20160039840
    Abstract: The present invention discloses a compound comprising the formula: wherein R is hydrogen or an alkyl group having from one to ten carbon atoms, or a compound of the formula wherein the S is replaced by CH2, and optionally comprising a pharmaceutically acceptable salt, hydrate, or solvate thereof. A method of treating a patient having cancer or a disease comprising administering to a patient an effective amount of the compound or pharmaceutically acceptable salt, hydrate, or solvate thereof.
    Type: Application
    Filed: August 7, 2015
    Publication date: February 11, 2016
    Inventor: Aleem Gangjee
  • Bicyclic and Tricyclic Pyrimidine Tyrosine Kinase Inhibitors with Antitubulin Activity and Methods of Treating a Patient
    Publication number: 20160009731
    Abstract: Bicyclic and tricyclic pyrimidine tyrosine kinase inhibitors with antitubulin activity are provided in the present invention. The compositions of the present invention possess dual activity in a single agent of potent vascular endothelial growth factor receptor inhibitory activity as well as antitubulin activity. Water soluble salts of these compositions are also described. Methods of treating a patient having cancer, macular degeneration, and arthritis with the compositions and salts thereof of the present invention are disclosed.
    Type: Application
    Filed: September 21, 2015
    Publication date: January 14, 2016
    Inventor: Aleem Gangjee
  • Substituted Bicyclic Pyrimidine Compounds with Tubulin and Multiple Receptor Inhibition
    Publication number: 20150284398
    Abstract: This invention provides substituted bicyclic pyrimidine compounds and pharmaceutically acceptable salts, hydrates, and solvates of the compounds, each having tubulin and multiple receptor inhibition properties. Methods of treating a patient diagnosed with cancer is disclosed comprising administering to the patient a therapeutically effective amount of the substituted bicyclic pyrimidine compounds and pharmaceutically acceptable salts, hydrates, and solvates of the compounds, for treating cancer.
    Type: Application
    Filed: April 3, 2015
    Publication date: October 8, 2015
    Inventor: Aleem Gangjee
  • Bicyclic and tricyclic pyrimidine tyrosine kinase inhibitors with antitubulin activity and methods of treating a patient
    Patent number: 9139590
    Abstract: Bicyclic and tricyclic pyrimidine tyrosine kinase inhibitors with antitubulin activity are provided in the present invention. The compositions of the present invention possess dual activity in a single agent of potent vascular endothelial growth factor receptor inhibitory activity as well as antitubulin activity. Water soluble salts of these compositions are also described. Methods of treating a patient having cancer, macular degeneration, and arthritis with the compositions and salts thereof of the present invention are disclosed.
    Type: Grant
    Filed: February 2, 2012
    Date of Patent: September 22, 2015
    Assignee: Duquesne University of the Holy Spirit
    Inventor: Aleem Gangjee
  • Tricyclic Compounds Having Antimitotic and/or Antitumor Activity and Methods of Use Thereof
    Publication number: 20150252053
    Abstract: The present invention provides tricyclic compounds, pharmaceutically acceptable salts, prodrugs, solvates, or hydrates thereof, having antimitotic activity, anti-multidrug resistance activity, for example P-glycoprotein inhibition, and antitumor activity, and which inhibit paclitaxel sensitive and resistant tumor cells. Also provided are methods of utilizing these compounds for treating tumor cells and inhibiting mitosis of cancerous cells.
    Type: Application
    Filed: May 22, 2015
    Publication date: September 10, 2015
    Inventor: Aleem Gangjee
  • Tricyclic Compounds Having Antimitotic and/or Antitumor Activity and Methods of Use Thereof
    Publication number: 20150232477
    Abstract: The present invention provides tricyclic compounds, pharmaceutically acceptable salts, solvates, or hydrates thereof, having antimitotic activity, anti-multidrug resistance activity, for example P-glycoprotein inhibition, and antitumor activity, and which inhibit paclitaxel sensitive and resistant tumor cells. Also provided are methods of utilizing these compounds for treating tumor cells and inhibiting mitosis of cancerous cells.
    Type: Application
    Filed: April 29, 2015
    Publication date: August 20, 2015
    Inventor: Aleem Gangjee
  • Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof
    Patent number: 9056869
    Abstract: The present invention provides tricyclic compounds, pharmaceutically acceptable salts, prodrugs, solvates, or hydrates thereof, having antimitotic activity, anti-multidrug resistance activity, for example P-glycoprotein inhibition, and antitumor activity, and which inhibit paclitaxel sensitive and resistant tumor cells. Also provided are methods of utilizing these compounds for treating tumor cells and inhibiting mitosis of cancerous cells.
    Type: Grant
    Filed: June 2, 2011
    Date of Patent: June 16, 2015
    Assignee: Duquesne University of the Holy Spirit
    Inventor: Aleem Gangjee